Background. Pure red-cell aplasia (PRCA) after erythropoietin (Epo) administration due to the appearance of neutralizing anti-Epo antibodies has been reported in over
Introduction
The gene for human erythropoietin (Epo) was cloned and expressed in 1985 [1, 2] and recombinant human Epo was approved for marketing in 1987 in the United States and in 1988 in Switzerland. During the 1990s, despite the liberal use of Epo in clinical practice, only three cases were reported worldwide in which anti-Epo antibodies (Ab) were detected after Epo administration [3] [4] [5] .
However, in February 2002, Casadevall et al.
[6] published a series of 13 patients on chronic dialysis who developed pure red-cell aplasia (PRCA) due to neutralizing anti-Epo Ab while receiving Epo therapy. By now, over 200 cases of PRCA occurring after Epo administration have been reported, most often to the manufacturers and/or health authorities [7] [8] [9] . The presence of anti-Epo Ab was not documented in all of them. This occurrence has now led to important changes in the determination of Epo type and mode of administration (www.swissmedic.ch/cgi7news) [10, 11] .
When the first two cases were observed in Switzerland by one of the authors (C.S.), the Swiss Society of Nephrology asked through its Dialysis Committee, with the help of the Swissmedic Pharmacovigilance Section, for the setting up of a systematic survey of the observed cases among dialysis patients. We report here the results of this investigation.
Subjects and methods
A questionnaire was set up and sent in January 2003 to the nephrologist in charge of each of the 69 dialysis units in Switzerland (among which are three paediatric units). We asked about the occurrence of past or present cases of end-stage renal disease patients with suspected or proven diagnosis of PRCA due to anti-Epo Ab. The period of survey extended between 1998 and June 2002, since during summer 2002, due to the occurrence of the syndrome, important changes in Epo administration were introduced. In addition, information on the number of patients treated by dialysis at the end of 2002 was also requested. The dialysis staffs of the centres that did not respond or returned incomplete data were interviewed directly by telephone.
The clinical, diagnostic and therapeutic data of the suspected cases were collected and compared with the information already obtained by the Swissmedic Pharmacovigilance Section and by the national branches of the manufacturers. Only cases with positive anti-Epo Ab were considered for analysis. Just the Epo-a and -b brands were available during the survey period, since darbepoietin only became available in Switzerland in September 2002. According to different sources, the a brand constituted 70% and the b brand 30% of the total sales for dialysis patients during the observation period.
Results
All the 69 Swiss dialysis centres participated in the survey. A total of five cases of confirmed PRCA with a positive test for neutralizing anti-Epo Ab were identified. Their characteristics and clinical evolution are summarized in Table 1 .
In addition to the positive anti-Epo Ab test, a bone marrow biopsy was compatible with PRCA in all cases and other causes of PRCA had been excluded on clinical, biological and serological grounds. All were treated by chronic haemodialysis for 9 months and developed refractory anaemia after a median of 10 months (range: 7-54 months) of Epo therapy.
According to our information, only Epo-a had been used in two cases, one patient had received Epo-b exclusively and in the two remaining cases both a and b brands had been administered. In those last two cases, Epo-a had been given first at doses increasing from 7500 to 12 000 U/week for 2 and 5 months, respectively, and then replaced by Epo-b at 7000 to 20 000 U/week for 5 and 7 months, respectively, before the diagnosis of PRCA was made.
The clinical evolution was interesting in several aspects: in two cases a remission occurred spontaneously 3 and 6 months after Epo withdrawal without any immunosuppressive therapy; in another case PRCA persisted clinically after kidney transplantation, requiring blood transfusions for 6 months, however, the anti-Epo Ab are still positive, despite immunosuppressive therapy, 3 years after transplantation and 3.5 years after Epo withdrawal. Cases 2 and 3 are reported in detail elsewhere [12, 13] .
Since all the dialysis units responded to this survey, the prevalence of PRCA due to anti-Epo Ab in Switzerland could be calculated. With 69 dialysis units in a country of 7.3 million inhabitants, Switzerland has a high density of dialysis centres. During 2002, the incidence and prevalence of chronic dialysis patients were 115 and 343 per million inhabitants, respectively. According to our survey, at the end of 2002, a total of 2555 patients were treated by chronic dialysis: 2237 by haemodialysis (among which 27 were haemodialyzed at home) and 318 by peritoneal dialysis. These numbers had been increasing only slowly over the preceding 4 years. This means that with five cases for around 2500 dialysis patients, Switzerland has a higher prevalence (1/500) than its surrounding countries: France with 33 cases out of 28 000 chronic dialysis patients (1/848), Germany with six out of 58 000 (1/9666) and Italy with four out of 36 000 (1/9000) [8, 14] .
Those diverse prevalences can be explained, at least partly, by the varying uses of Epo in the different countries and their administration mode [10] . According to our survey, during the first part of 2002, 90% of the total dialysis population was treated with Epo, among which 79.4% were treated subcutaneously (s.c.) and 20.6% intravenously (i.v.). Based on those results it appears that, when considering the two Epo brands together, the five cases were observed in a weighted chronic dialysis population of 2500, in an Epo-treated dialysis population of around 2300 patients or in about 9900 dialysis patient-years of exposure to Epo during a 4.3 year period. According to various sources, during the survey period the a brand constituted 70% of the sales to the chronic dialysis units in Switzerland. When restricted to the pure cases, this prevalence becomes 1/1150 for only Epo-a-treated patients and 1/2300 for only Epo-b patients.
Discussion
The present survey identified five cases of PRCA occurring during Epo therapy in chronic dialysis patients in Switzerland. Some of our observations shed additional light on the clinical evolution of Epo-related PRCA: while, so far, a spontaneous remission appears exceptional [8] , in our cases 4 and 5, a remission of the syndrome occurred spontaneously without any immunosuppressive therapy, respectively, Table 1 . Characteristics and clinical evolution of the PRCA cases due to anti-Epo Ab during Epo administration in chronic dialysis patients in Switzerland Case no. MPGP, membranoproliferative glomerulopathy; HCV, chronic hepatitis C; HD, haemodialysis; RA, refractory anaemia; TI, transfusion independence; CsA, cyclosporin A; ATG, anti-thymocyte globulin; TD, transfusion dependent; Hb, haemoglobin; GFR, glomerular filtration rate.
3 and 6 months after Epo withdrawal. In contrast, while kidney transplantation is reported to cure PRCA syndrome within a few weeks [6] [7] [8] , in our case 2, PRCA persisted clinically, necessitating blood transfusions during 6 months after an otherwise successfully functioning kidney transplant and the anti-Epo Ab still remain positive 3 years after transplantation, with haemoglobin levels oscillating spontaneously between 64 and 82 g/l [13] .
The most interesting observation of this survey is the high prevalence of PRCA due to anti-Epo Ab observed in Switzerland: five cases for a chronic dialysis population receiving Epo of 2300 and an exposure rate of 9900 patient-years during a 4.3 year period. Even if this total population remains low when compared with other countries, it has to be noted that in France, despite the initial report by Casadevall et al. [6] and the subsequent increased awareness, a lower prevalence is observed [10] . The prevalence is also much lower in other neighbouring countries, such as Germany and Italy. It is presently estimated that the incidence of PRCA due to anti-Epo Ab is one to two per 10 000 dialysis patients receiving Epo by the s.c. route [11] . Due to the changes in the manufacturing, handling and prescription mode introduced for the Epo-a brand during summer 2002, the occurrence of new cases seems to be decreasing.
The national discrepancies appear multifactorial. In France, the patient has to go to the pharmacy in person to obtain the product with a subsequent greater risk of cold-chain disruption, while in Germany and Italy, Epo is routinely administered by the dialysis staff and much more often by the i.v. route. In Switzerland, Epo is generally ordered and stocked directly by the dialysis unit or hospital pharmacy and administered most often s.c., directly by the dialysis staff.
Several factors can be put forward to explain the high frequency of PRCA cases due to anti-Epo Ab observed in Switzerland:
(i) Since in our country Epo was admitted and reimbursed very early for chronic dialysis patients, it could be prescribed without financial or administrative constraints, which explains why 90% of chronic dialysis patients received Epo. (ii) On the basis of a national multicentre study [15] [8, 11] . (iii) Among the two different brands of Epo available, the a formulation was used in almost 70% of the Swiss patients during the observation period. Since that time, the a brand has been shown to represent a greater risk, which led the manufacturer to forbid its s.c. use in December 2002 (www.swissmedic.ch/cgi7news). (iv) The possibility of a ruptured cold-chain was first suggested by the fact that two of the five cases were observed in the same dialysis centre, but they occurred in a 2 year time interval and the handling of the medication was repeatedly investigated by the hospital pharmacist, who ruled out this possibility; moreover, in none of the five cases was self-administration practised at home, which makes this hypothesis less likely.
It must also be added that due to the mandatory declaration to Swiss health authorities of any clinical syndrome suspected of PRCA during Epo administration and the simultaneous 100% response rate of the present survey, the prevalence reported here corresponds to the real prevalence, which is not necessarily the case in other countries.
Indeed, a recent Editorial proposed the setting up of a dedicated independent registry devoted to the Epo-induced PRCA syndrome, in order to obtain a clearer view of its occurrence and outcome [11] . Our survey appears as an original step in this direction and seems to indicate that the prevalence might be underestimated at present.
In conclusion, the prevalence of PRCA after Epo administration in dialysis patients appears particularly high in Switzerland. Among the potential explanations, the most plausible are the large use of Epo in dialysis patients, the almost exclusive s.c. administration, the larger market distribution of the Epo-a brand, the eventual disruption of the cold chain and the setting up of a systematic national survey.
